Cite
Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial.
MLA
Chudy, Onwugaje, Kenechukwu, et al. “Aspirin, Ibuprofen, and Reduced Risk of Advanced Colorectal Adenoma Incidence and Recurrence and Colorectal Cancer in the PLCO Cancer Screening Trial.” Cancer (0008543X), vol. 127, no. 17, Sept. 2021, pp. 3145–55. EBSCOhost, https://doi.org/10.1002/cncr.33623.
APA
Chudy, O. K., Huang, W., Su, L. J., Purdue, M. P., Johnson, C. C., Wang, L., Katki, H. A., Barry, K. H., & Berndt, S. I. (2021). Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial. Cancer (0008543X), 127(17), 3145–3155. https://doi.org/10.1002/cncr.33623
Chicago
Chudy, Onwugaje, Kenechukwu, Wen‐Yi Huang, L. Joseph Su, Mark P. Purdue, Christine C. Johnson, Lingxiao Wang, Hormuzd A. Katki, Kathryn Hughes Barry, and Sonja I. Berndt. 2021. “Aspirin, Ibuprofen, and Reduced Risk of Advanced Colorectal Adenoma Incidence and Recurrence and Colorectal Cancer in the PLCO Cancer Screening Trial.” Cancer (0008543X) 127 (17): 3145–55. doi:10.1002/cncr.33623.